Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer

Anthracyclines, such as doxorubicin, are used as first-line chemotherapeutics, usually in combination therapies, for the treatment of advanced breast cancer. While these drugs have been successful therapeutic options, their use is limited due to serious drug related toxicities and acquired tumor res...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Translational oncology Jg. 11; H. 4; S. 988 - 998
Hauptverfasser:	Hasim, Mohamed S., Nessim, Carolyn, Villeneuve, Patrick J., Vanderhyden, Barbara C., Dimitroulakos, Jim
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 01.08.2018 Elsevier
ISSN:	1936-5233, 1936-5233
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!